Sarepta Halts Elevidys Gene Therapy Shipments

Sarepta Therapeutics announced on Monday its decision to suspend shipments of the Elevidys gene therapy across the United States. This move comes after a muscular dystrophy patient died following an experimental treatment.

Last Friday, U.S. regulators had advised the company to voluntarily suspend shipments of the gene therapy. Initially, Sarepta declined to comply.

However, the company later issued a statement confirming that shipments for Duchenne muscular dystrophy would cease temporarily by the end of business on Tuesday.